{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:04:01Z","timestamp":1789646641094,"version":"4.0.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"DOI":"10.1007\/s40801-026-00582-6","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:25:14Z","timestamp":1789644314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimated Acquisition Cost Differences between Fixed and Simulated Body Weight-Based Nivolumab Dosing Using Real-World Claims Data in Japan"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4579-4565","authenticated-orcid":false,"given":"Tomohiko","family":"Harada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9110-9604","authenticated-orcid":false,"given":"Yoshihiro","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Ohnishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5161-0035","authenticated-orcid":false,"given":"Rikuto","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7743-5231","authenticated-orcid":false,"given":"Tomoya","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2486-8169","authenticated-orcid":false,"given":"Tomoaki","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"582_CR1","unstructured":"Ono Pharmaceutical Co., Ltd. Opdivo\u00ae (nivolumab) Interview Form. https:\/\/www.info.pmda.go.jp\/go\/interview\/1\/180188_4291427A1024_1_047_1F.pdf. Accessed 20 Apr 2026."},{"issue":"6230","key":"582_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56\u201361. https:\/\/doi.org\/10.1126\/science.aaa8172.","journal-title":"Science"},{"issue":"18","key":"582_CR3","doi-asserted-by":"publisher","first-page":"5394","DOI":"10.1158\/1078-0432.CCR-16-2842","volume":"23","author":"Y Feng","year":"2017","unstructured":"Feng Y, Wang X, Bajaj G, et al. Nivolumab exposure\u2013response analyses of efficacy and safety in previously treated squamous or nonsquamous non-small cell lung cancer. Clin Cancer Res. 2017;23(18):5394\u2013405. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2842.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"582_CR4","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/annonc\/mdx235","volume":"28","author":"X Zhao","year":"2017","unstructured":"Zhao X, Suryawanshi S, Hruska M, et al. Assessment of nivolumab benefit\u2013risk profile of a 240-mg flat dose relative to a 3-mg\/kg dosing regimen in patients with advanced tumors. Ann Oncol. 2017;28(8):2002\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdx235.","journal-title":"Ann Oncol"},{"key":"582_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejca.2019.02.016","volume":"113","author":"A Bayle","year":"2019","unstructured":"Bayle A, Besse B, Annereau M, et al. Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: what is the economic impact? Eur J Cancer. 2019;113:28\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2019.02.016.","journal-title":"Eur J Cancer"},{"issue":"4","key":"582_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040730","volume":"8","author":"S Monirul","year":"2020","unstructured":"Monirul S, Rigal M, Chouahnia K, et al. Budget impact analysis of fixed-dose versus weight-based dosing regimen of nivolumab and pembrolizumab in the treatment of non-small cell lung cancer. Vaccines (Basel). 2020;8(4):730. https:\/\/doi.org\/10.3390\/vaccines8040730.","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"582_CR7","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/cam4.2888","volume":"9","author":"E Hall","year":"2020","unstructured":"Hall E, Zhang J, Kim EJ, et al. Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. Cancer Med. 2020;9(6):2106\u201312. https:\/\/doi.org\/10.1002\/cam4.2888.","journal-title":"Cancer Med"},{"issue":"6","key":"582_CR8","doi-asserted-by":"publisher","first-page":"e767","DOI":"10.1097\/MJT.0000000000000774","volume":"25","author":"S Mukherjee","year":"2018","unstructured":"Mukherjee S, Ibrahimi S, Machiorlatti M, et al. Personalized dosing versus fixed dosing of immune checkpoint inhibitors: a cost analysis study. Am J Ther. 2018;25(6):e767\u20138. https:\/\/doi.org\/10.1097\/MJT.0000000000000774.","journal-title":"Am J Ther"},{"key":"582_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920974203","volume":"12","author":"AR Farooq","year":"2020","unstructured":"Farooq AR, O\u2019Brien T, O\u2019Reilly S. Is flat dosing cost-effective? Re: \u201cThe same old story\u201d: thoughts on authorised doses of anticancer drugs. Ther Adv Med Oncol. 2020;12:1758835920974203. https:\/\/doi.org\/10.1177\/1758835920974203.","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"582_CR10","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1016\/S1470-2045(22)00554-X","volume":"23","author":"R Malmberg","year":"2022","unstructured":"Malmberg R, Zietse M, Dumoulin DW, et al. Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. Lancet Oncol. 2022;23(12):e552\u201361. https:\/\/doi.org\/10.1016\/S1470-2045(22)00554-X.","journal-title":"Lancet Oncol"},{"key":"582_CR11","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00228-020-02839-7","volume":"76","author":"N Boone","year":"2020","unstructured":"Boone N, van Bodegraven AA. Less is more: a cost benefit analysis of a changed posology for nivolumab. Eur J Clin Pharmacol. 2020;76:739\u201340. https:\/\/doi.org\/10.1007\/s00228-020-02839-7.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"582_CR12","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cpt.875","volume":"103","author":"K Ogungbenro","year":"2018","unstructured":"Ogungbenro K, Patel A, Duncombe R, et al. Dose rationalization of pembrolizumab and nivolumab using pharmacokinetic modeling and simulation and cost analysis. Clin Pharmacol Ther. 2018;103(4):582\u201390. https:\/\/doi.org\/10.1002\/cpt.875.","journal-title":"Clin Pharmacol Ther"},{"key":"582_CR13","unstructured":"e-Stat. National Health and Nutrition Survey: Mean and standard deviation of height and body weight. https:\/\/www.e-stat.go.jp\/dbview?sid=0003224177. Accessed 20 Apr 2026."},{"issue":"2","key":"582_CR14","doi-asserted-by":"publisher","first-page":"46","DOI":"10.37737\/ace.25006","volume":"7","author":"H Yasunaga","year":"2025","unstructured":"Yasunaga H. DeSC database. Ann Clin Epidemiol. 2025;7(2):46\u20139. https:\/\/doi.org\/10.37737\/ace.25006.","journal-title":"Ann Clin Epidemiol"},{"key":"582_CR15","doi-asserted-by":"publisher","DOI":"10.37737\/ace.26007","author":"T Morita","year":"2025","unstructured":"Morita T, Sasabuchi Y, Yasunaga H. Effect of a financial incentive scheme on promoting prescription of biosimilars: a interrupted time-series analyses. Ann Clin Epidemiol. 2025. https:\/\/doi.org\/10.37737\/ace.26007.","journal-title":"Ann Clin Epidemiol"},{"key":"582_CR16","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA), Japan. Review Report: Opdivo Intravenous Infusion. August 7, 2018."},{"key":"582_CR17","unstructured":"Bristol-Myers Squibb. Clinical Protocol CA209227: BMS-936558 (nivolumab). Revised Protocol No. 06. August 15, 2018."},{"issue":"11","key":"582_CR18","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1093\/annonc\/mdy408","volume":"29","author":"GV Long","year":"2018","unstructured":"Long GV, Tykodi SS, Schneider JG, et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol. 2018;29(11):2208\u201313. https:\/\/doi.org\/10.1093\/annonc\/mdy408.","journal-title":"Ann Oncol"},{"key":"582_CR19","unstructured":"IQVIA Japan. IQVIA Topline Market Data: Pharmaceutical Sales in Japan, Fiscal Year 2022 (April 2022\u2013March 2023). https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/japan\/topline-market-data\/2023\/toplinedata_fy_2022.pdf. Accessed 20 Apr 2026."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00582-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00582-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00582-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:25:18Z","timestamp":1789644318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00582-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":19,"alternative-id":["582"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00582-6","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted using anonymized secondary data obtained from a claims database. The study was performed in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects issued by the Ministry of Health, Labour and Welfare of Japan. The study protocol was approved by the Ethics Committee of Gifu Pharmaceutical University (approval number: 7-40). Because this study used anonymized existing data and involved no direct contact with human participants, the requirement for informed consent was waived.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived due to the use of anonymized data and the retrospective nature of the study.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are available from DeSC Healthcare, Inc.; however, restrictions apply to their availability because the data were used under license for the current study and are not publicly available.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The code used for the analyses is available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TH and YN conceived the idea and design of the study. TH, YN, AO, RM, TS, and TY analyzed and interpreted the data. TH, YN, AO, and RM collected and assembled the data. TH and YN drafted the manuscript. TH, YN, and TY critically revised the manuscript for important intellectual content. All the authors have read and approved the final manuscript.","order":7,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this manuscript, the authors used ChatGPT (OpenAI) to assist with language editing, clarification of wording, and refinement of manuscript structure and presentation. The tool was not used to generate, analyze, or interpret the study data. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the final content of the manuscript.","order":8,"name":"Ethics","label":"Declaration of Generative Artificial Intelligence (AI) in the Writing Process","group":{"name":"EthicsHeading","label":"Declarations"}}]}}